Cargando…

Effects of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) on the Glucose and Fat Metabolism Biomarkers Leptin and Fructosamine

(1) Background: Heart failure with reduced ejection fraction (HFrEF) remains a major health burden. Angiotensin-Receptor-Neprilysin-Inhibitors (ARNIs) are an established HFrEF therapy which increases natriuretic peptide levels by inhibiting neprilysin. Leptin is a lipid metabolism parameter, which i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohnewein, Bernhard, Shomanova, Zornitsa, Paar, Vera, Topf, Albert, Jirak, Peter, Fiedler, Lukas, Granitz, Christina, Van Almsick, Vincent, Semo, Dilvin, Zagidullin, Naufal, Dieplinger, Anna-Maria, Sindermann, Juergen, Reinecke, Holger, Hoppe, Uta C., Pistulli, Rudin, Motloch, Lukas J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179018/ https://www.ncbi.nlm.nih.gov/pubmed/37176525 http://dx.doi.org/10.3390/jcm12093083

Ejemplares similares

Dexamethasone Improves Cardiovascular Outcomes in Critically Ill COVID-19, a Real World Scenario Multicenter Analysis
por: Jirak, Peter, et al.
Publicado: (2022)

Gender-Specific Differences in the Intensive Care Treatment of COVID-19 Patients
por: Jirak, Peter, et al.
Publicado: (2022)

Classic and Novel Biomarkers as Potential Predictors of Ventricular Arrhythmias and Sudden Cardiac Death
por: Shomanova, Zornitsa, et al.
Publicado: (2020)

Higher Incidence of Stroke in Severe COVID-19 Is Not Associated With a Higher Burden of Arrhythmias: Comparison With Other Types of Severe Pneumonia
por: Jirak, Peter, et al.
Publicado: (2021)

SERUM BIOMARKERS HS-TNI AND SST-2 PREDICT LONG-TERM RISK FOR CARDIOVASCULAR EVENTS IN DISCHARGED HOSPITALIZED COVID-19 SURVIVORS
por: Zagidullin, Naufal, et al.
Publicado: (2023)

Analysis of Selected Cardiovascular Biomarkers in Takotsubo Cardiomyopathy and the Most Frequent Cardiomyopathies
por: Topf, Albert, et al.
Publicado: (2021)

Investigation of hs-TnI and sST-2 as Potential Predictors of Long-Term Cardiovascular Risk in Patients with Survived Hospitalization for COVID-19 Pneumonia
por: Fiedler, Lukas, et al.
Publicado: (2022)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
por: Sutanto, Henry, et al.
Publicado: (2021)

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

Pathophysiology of Calcium Mediated Ventricular Arrhythmias and Novel Therapeutic Options with Focus on Gene Therapy
por: Paar, Vera, et al.
Publicado: (2019)

Prophylactic rivaroxaban in the early post-discharge period reduces the rates of hospitalization for atrial fibrillation and incidence of sudden cardiac death during long-term follow-up in hospitalized COVID-19 survivors
por: Fiedler, Lukas, et al.
Publicado: (2023)

Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors
por: Motloch, Lukas J., et al.
Publicado: (2022)

Higher incidence of stroke in severe COVID-19 is not associated with a higher burden of arrhythmias: comparison to other types of severe pneumonia
por: Jirak, P, et al.
Publicado: (2021)

Myocardial injury in severe COVID‐19 is similar to pneumonias of other origin: results from a multicentre study
por: Jirak, Peter, et al.
Publicado: (2020)

Impact of cavotricuspid isthmus ablation for typical atrial flutter and heart failure in the elderly—results of a retrospective multi-center study
por: Boxhammer, Elke, et al.
Publicado: (2023)

Cardiovascular Biomarkers for Prediction of in-hospital and 1-Year Post-discharge Mortality in Patients With COVID-19 Pneumonia
por: Motloch, Lukas J., et al.
Publicado: (2022)

LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
por: Lefkowitz, Martin P
Publicado: (2011)

The Diagnostic and Therapeutic Value of Multimarker Analysis in Heart Failure. An Approach to Biomarker-Targeted Therapy
por: Topf, Albert, et al.
Publicado: (2020)

LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
por: Lefkowitz, Martin P
Publicado: (2015)

Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls
por: Jirak, Peter, et al.
Publicado: (2020)

Combining Novel Biomarkers for Risk Stratification of Two-Year Cardiovascular Mortality in Patients with ST-Elevation Myocardial Infarction
por: Zagidullin, Naufal, et al.
Publicado: (2020)

Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists
por: Dalal, Jamshed, et al.
Publicado: (2023)

Beneficial Effects of Combined AT(1) Receptor/Neprilysin Inhibition (ARNI) Versus AT(1) Receptor Blockade Alone in the Diabetic Eye
por: Prasad, Tuhina, et al.
Publicado: (2016)

Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis
por: Rattanavipanon, Wipharak, et al.
Publicado: (2021)

Differences of Hemogram Parameters and Their Ratios among Patients with Takotsubo Syndrome, Acute Coronary Syndrome and Healthy Individuals
por: Topf, Albert, et al.
Publicado: (2022)

Impella use in real-world cardiogenic shock patients: Sobering outcomes
por: Abdullah, Khaled Q. A., et al.
Publicado: (2021)

Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study
por: Wang, Xiaobo, et al.
Publicado: (2023)

Comparison of native myocardial T1 and T2 mapping at 1.5T and 3T in healthy volunteers: Reference values and clinical implications
por: Granitz, Marcel, et al.
Publicado: (2018)

J-waves in acute COVID-19: A novel disease characteristic and predictor of mortality?
por: Zagidullin, Naufal Shamilevich, et al.
Publicado: (2021)

A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis
por: Jariwala, Pankaj, et al.
Publicado: (2021)

From ARB to ARNI in Cardiovascular Control
por: Uijl, Estrellita, et al.
Publicado: (2016)

My gratitude for Arny's friendship with me
por: Õmura, Satoshi
Publicado: (2021)

Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension
por: King, Nicholas E., et al.
Publicado: (2022)

Pharmacological Targeting of the RAGE-NFκB Signalling Axis Impedes Monocyte Activation under Diabetic Conditions through the Repression of SHP-2 Tyrosine Phosphatase Function
por: Dorenkamp, Marc, et al.
Publicado: (2023)

Can ARNI Prevent Doxorubicin-Induced Cardiotoxicity?
por: Özgür Barış, Veysel, et al.
Publicado: (2022)

Differential Diagnosis between Takotsubo Syndrome and Acute Coronary Syndrome—A Prospective Analysis of Novel Cardiovascular Biomarkers for a More Selective Triage
por: Topf, Albert, et al.
Publicado: (2022)

Pretreatment with Betablockers, a Potential Predictor of Adverse Cardiovascular Events in Takotsubo Syndrome
por: Topf, Albert, et al.
Publicado: (2022)

Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure
por: Jirak, Peter, et al.
Publicado: (2017)

ARNi: A Novel Approach to Counteract Cardiovascular Diseases
por: Volpe, Massimo, et al.
Publicado: (2019)

The Value of Fetuin-A as a Predictor to Identify Takotsubo Patients at Risk of Cardiovascular Events
por: Topf, Albert, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ec2tier5lvre9d4nj3qsngmp73